Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics


Ionis Pharmaceuticals, Inc. (IONS): $36.20

-1.00 (-2.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IONS POWR Grades


  • IONS scores best on the Value dimension, with a Value rank ahead of 59.75% of US stocks.
  • IONS's strongest trending metric is Growth; it's been moving up over the last 48 weeks.
  • IONS's current lowest rank is in the Sentiment metric (where it is better than 12.06% of US stocks).

IONS Stock Summary

  • With a year-over-year growth in debt of 61.96%, Ionis Pharmaceuticals Inc's debt growth rate surpasses 87.89% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Ionis Pharmaceuticals Inc is reporting a growth rate of -199.87%; that's higher than merely 10.42% of US stocks.
  • As for revenue growth, note that IONS's revenue has grown -26.88% over the past 12 months; that beats the revenue growth of merely 9.85% of US companies in our set.
  • Stocks that are quantitatively similar to IONS, based on their financial statements, market capitalization, and price volatility, are ACRS, XBIT, RETA, RESN, and SWKS.
  • Visit IONS's SEC page to see the company's official filings. To visit the company's web site, go to www.ionispharma.com.

IONS Valuation Summary

  • IONS's price/sales ratio is 8.2; this is 115.79% higher than that of the median Healthcare stock.
  • IONS's price/sales ratio has moved down 11.1 over the prior 243 months.
  • Over the past 243 months, IONS's price/sales ratio has gone down 11.1.

Below are key valuation metrics over time for IONS.

Stock Date P/S P/B P/E EV/EBIT
IONS 2021-08-31 8.2 9.6 -10.4 -32.9
IONS 2021-08-30 8.0 9.5 -10.2 -32.4
IONS 2021-08-27 8.1 9.6 -10.3 -32.8
IONS 2021-08-26 8.0 9.4 -10.1 -32.2
IONS 2021-08-25 8.1 9.6 -10.3 -32.7
IONS 2021-08-24 8.2 9.7 -10.4 -33.0

IONS Growth Metrics

  • The 5 year price growth rate now stands at -9.97%.
  • Its 3 year cash and equivalents growth rate is now at 302.64%.
  • Its 4 year revenue growth rate is now at 271.62%.
Over the past 33 months, IONS's revenue has gone up $107,857,000.

The table below shows IONS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 687.717 -29.694 -541.959
2021-03-31 707.504 -11.186 -492.929
2020-12-31 729.264 35.892 -451.286
2020-09-30 932.664 215.847 73.401
2020-06-30 940.477 213.398 130.508
2020-03-31 958.753 230.431 161.477

IONS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IONS has a Quality Grade of C, ranking ahead of 48.12% of graded US stocks.
  • IONS's asset turnover comes in at 0.269 -- ranking 165th of 677 Pharmaceutical Products stocks.
  • WVE, CORT, and VCEL are the stocks whose asset turnover ratios are most correlated with IONS.

The table below shows IONS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.269 0.983 -0.073
2021-03-31 0.262 0.983 -0.051
2020-12-31 0.250 0.984 -0.031
2020-09-30 0.298 0.990 0.050
2020-06-30 0.306 0.992 0.063
2020-03-31 0.317 0.994 0.072

IONS Price Target

For more insight on analysts targets of IONS, see our IONS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.82 Average Broker Recommendation 1.82 (Hold)

IONS Stock Price Chart Interactive Chart >

Price chart for IONS

IONS Price/Volume Stats

Current price $36.20 52-week high $64.37
Prev. close $37.20 52-week low $34.43
Day low $36.10 Volume 445,800
Day high $37.47 Avg. volume 1,298,283
50-day MA $37.87 Dividend yield N/A
200-day MA $45.00 Market Cap 5.11B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio


Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.


IONS Latest News Stream


Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream


Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi1-3The ASCEND study aims to evaluate whether treatment with a higher dose of nusinersen has the potential to improve clinical outcomes in these patientsBuilding on the proven efficacy and well-established safety of the currently approved 12-milligram dose, patients in this study will receive an investigational higher dose of nusinersen, which is also being ev

Yahoo | September 15, 2021

Huntington Disease Protein Market Size Analysis, Industry Outlook, Regional Forecast 2021-2027| AFFiRiS AG, Ionis Pharmaceuticals, Inc., Neurimmune Holding AG

Huntingtin is found in a large number of the body''s tissues, with the most elevated levels of action in the mind. Inside cells, this protein might be associated with substance flagging, shipping materials, connecting (restricting) to proteins and different constructions,

OpenPR | September 3, 2021

Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting

CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighting new scientific insights from its ATTR amyloidosis

Business Insider Markets | September 3, 2021

Ionis Pharmaceuticals (IONS) Up 3% Since Last Earnings Report: Can It Continue?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2021

Ionis to present at upcoming virtual investor conferences

CARLSBAD, Calif., Sept. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following

Business Insider Markets | September 2, 2021

Read More 'IONS' Stories Here

IONS Price Returns

1-mo -6.94%
3-mo -7.01%
6-mo -19.48%
1-year -25.67%
3-year -29.56%
5-year 3.78%
YTD -35.97%
2020 -6.41%
2019 11.75%
2018 7.48%
2017 5.16%
2016 -22.77%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8282 seconds.